timothy sykes logo
REPL Soars As Trump FDA Shake-Up Revives RP1 Hopes Thumbnail
G Google News

REPL Soars As Trump FDA Shake-Up Revives RP1 Hopes

ELLIS HOBBS•UPDATED MAY. 10, 2026, 10:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Replimune Group Inc. soared as positive trial news boosted investor optimism; stocks have been trading up by 27.36 percent

Candlestick Chart

Weekly Update May 04 – May 08, 2026: On Sunday, May 10, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 27.36%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Replimune remains a pre‑commercial, clinical‑stage oncology company with no product revenue and structurally negative profitability, as evidenced by EBITDA of -$67.6m and net income of -$70.9m for the latest quarter. Cash and investments of ~$269m, working capital of ~$230m, and a current ratio of 5.6 provide a solid runway despite deeply negative ROE (-90.9%) and ROA (-67.2%). Modest leverage (total debt/equity 0.36, long‑term debt/capital 0.26) and EV of ~$143m imply the market is heavily discounting its pipeline.

Technically, the stock has reversed sharply from a tight 2.85–2.94 consolidation to a breakout week closing at 4.25, with a strong sequence of higher highs and higher lows and a notable gap up on May 8. Intraday 5‑minute action shows aggressive buying on volume through the 3.40–3.50 zone, now key support. Dominant trend is short‑term bullish; traders can use ~$3.50 as a stop level and target the next resistance band near $5.00.

Recent news flow is strongly supportive: a political pushback on the FDA and criticism of the RP1 melanoma rejection have driven a re‑rating, as investors reassess regulatory risk. Versus broader Healthcare and Biotech benchmarks, REPL screens higher‑risk but significantly more event‑driven, with asymmetric upside if RP1 is reconsidered or partnered. Base case: maintain a speculative Buy with $5.50–6.00 near‑term target, key support at $3.50 and intermediate resistance in the $4.80–5.00 area.

Quick Financial Overview

Replimune Group Inc. (REPL) has seen aggressive buying interest around the latest political and media pressure on the FDA. On the weekly tape, price moved from the low $2.90s to above $4.25 into 2026/05/08, a sharp upside breakout after a long base. The intraday 5‑minute candle showing a drive from roughly $3.32 to a $4.18 high, and closing near $4.07, confirms strong momentum with buyers in control into the close. For short-term traders, that pattern signals clear shift from apathy to speculative risk-on.

Under the hood, Replimune Group Inc. is still a classic cash-burning biotech. The latest quarterly numbers show net income from continuing operations at about -$70.9M with EBITDA around -$67.6M, driven mainly by $53.1M in research and $18.7M in G&A. On the positive side, the balance sheet holds roughly $269.1M in cash and short-term investments and working capital near $230.3M, with a strong current ratio of 5.6, giving the company a decent runway.

More Breaking News

Valuation metrics reflect this early-stage, loss-making profile. Enterprise value is about $143.3M, with price-to-book near 1.6 and negative cash-flow-based ratios, consistent with a development-stage biotech where the main asset is pipeline optionality. Returns on equity and assets are deeply negative, which is normal for a platform still in heavy build-out mode, but traders must respect that the business is not self-funding. For REPL, short-term price is being driven primarily by shifting odds around RP1 rather than near-term earnings power.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading REPL

Millionaire's
POV on REPL

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”